Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite marker for diagnosis of diabetic retinopathy and use thereof

A diabetic retina and biomarker technology, applied in biological testing, disease diagnosis, biomaterial analysis, etc., can solve the problems of unknown etiology, limited biomarkers of retinopathy, etc., and achieve the effect of high diagnostic ability

Pending Publication Date: 2021-10-22
RETI MARK CO LTD
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are problems in that the exact etiology is still unknown so far, and biomarkers for judging the degree of progression of retinopathy are very limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite marker for diagnosis of diabetic retinopathy and use thereof
  • Composite marker for diagnosis of diabetic retinopathy and use thereof
  • Composite marker for diagnosis of diabetic retinopathy and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Example 1: Selecting patients with diabetic retinopathy and collecting plasma

[0107] Plasma samples from patients with diabetic retinopathy were collected with approval from the Clinical Trial Review Board of Seoul National University Hospital, Bundang. For the quantitative detection of biomarkers, a total of 155 plasma samples were analyzed by plasma proteomics, and the clinical characteristics of the normal group (Non DMR) and the diabetic retinopathy (DMR) disease group that were analyzed are shown in Table 1 below .

[0108] Table 1

[0109] Sample clinical information

[0110]

[0111]

Embodiment 2

[0112] Example 2: Selection of Peptides and Quantitative Analysis of Peptides Using Multiple Reaction Monitoring Mass Spectrometry

[0113] 2-1: Selection of peptides and design of synthetic peptides

[0114] In the present invention, as biomarkers for the diagnosis of diabetic retinopathy, the following 13 were screened: IGFBP2 (insulin-like growth factor binding protein 2), ADAMTSL2 (ADAMTS-like protein 2), CFH (complement factor H), Cp (ceruloplasmin), DDI2 (protein DDI1 homolog 2), FCN2 (fibrin glue 2), LGALS3BP (galectin 3-binding protein), MBL2 (mannose-binding protein C), PNLIP (pancreatic triacyl glycerol lipase), SELE (E-selectin), SIGLEC14 (sialic acid binding immunoglobulin-like lectin 14), THBS1 (thrombospondin-1) and ZG16B (zymogen granulin 16 homolog B).

[0115] For multiple reaction monitoring analysis of the above biomarkers, representative peptides (Q1) with charge-to-mass ratio (m / z) specific to the proteins of the 13 biomarkers were selected and produc...

Embodiment 3

[0129] Example 3: Confirmation of Improved Diagnostic Capability Based on Combining Composite Biomarker Panel Results with Clinical Information

[0130] In the present invention, when combining the results of the 13 composite biomarker groups with clinical information, in order to confirm the improvement effect of diagnostic ability, the conversion information of biomarker expression level and the conversion degree of clinical information are input using the logistic regression model, and the classification is estimated from this is the probability of diabetic retinopathy.

[0131] table 3

[0132] Confirmation of Diabetic Retinopathy Diagnostic Performance Based on Combined Number of Composite Biomarkers

[0133]

[0134] 1. Clinical information, 2. LGALS3BP, 3. MBL2, 4. IGFBP2, 5. PNLIP, 6. ZG16B, 7. DDI2, 8. FCN2, 9. THBS1, 10. SIGLEC14, 11. CP, 12. ADAMTSL2, 13 .SELC, 14.CFH

[0135] Table 4

[0136] Confirmation of diagnostic capability based on combining composi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composite marker for diagnosis of diabetic retinopathy and a use thereof and, more particularly, to a composite marker, for diagnosis of diabetic retinopathy, comprising two or more blood markers specific for diagnosis of diabetic retinopathy and thus having an improved diagnostic performance. In addition, the present invention relates to a composition for diagnosis of diabetic retinopathy, a diagnostic kit, and a method for providing information necessary for diagnosing diabetic retinopathy, each of which uses the composite marker. The composite marker for diagnosis of diabetic retinopathy of the present invention was found to be superior to combinations of other markers in terms of sensitivity and diagnosis performance and to exhibit a high diagnostic potential for initial diabetic retinopathy, as analyzed for combinations between protein quantitation values of the composite marker and fundamental clinical information. In addition, the composite biomarker of the present invention does not use blood proteins for biopsy, but can conveniently perform analysis by means of patient plasma and thus can be advantageously applied to the early diagnosis of diabetic retinopathy.

Description

technical field [0001] The present invention relates to a composite biomarker for diagnosing diabetic retinopathy (diabetic retinopathy) and its use, and in more detail, relates to a combination of two or more blood biomarkers specific for the diagnosis of diabetic retinopathy to improve diagnostic performance Composite biomarkers for the diagnosis of diabetic retinopathy. Furthermore, it relates to a composition for diagnosing diabetic retinopathy, a diagnostic kit, and a method for providing information necessary for diagnosing diabetic retinopathy using the composite biomarker. Background technique [0002] Diabetic retinopathy (DR or DMR) is a typical complication of diabetes manifested when retinal microvessels are damaged, and is one of the three major blindness diseases in ophthalmology together with age-related macular degeneration and glaucoma. According to the Korea Health Insurance Review and Evaluation Service, the number of diabetic patients increased from appr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68C12Q1/6883
CPCC12Q1/6883G01N33/6893G01N2800/164G01N2800/60G01N2800/042C12Q2600/158C12Q2600/156
Inventor 朴晟濬李泳珠金惠林
Owner RETI MARK CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com